Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Carasent AB ( (SE:CARA) ) is now available.
Carasent AB reported strong full-year 2025 results, with net sales rising 25% to SEK 343.8 million, driven by 14% organic growth and contributions from acquisitions. The company significantly improved profitability, turning EBITDA to SEK 73.3 million from SEK 11.6 million, lifting the EBITDA margin to 21% and swinging to a SEK 34.8 million profit after tax, supported by a 14% increase in ARR and robust net retention of 110%.
In the fourth quarter, net sales grew 19% to SEK 93.6 million and organic growth reached 16%, while adjusted EBITDA margin climbed to 25%, reflecting improved operational efficiency. Operating cash flow strengthened to SEK 40.4 million for the year and free cash flow excluding acquisitions turned nearly breakeven, indicating healthier underlying cash generation despite a lower year-end cash balance as the company continues to invest in growth.
The most recent analyst rating on (SE:CARA) stock is a Hold with a SEK26.00 price target. To see the full list of analyst forecasts on Carasent AB stock, see the SE:CARA Stock Forecast page.
More about Carasent AB
Carasent AB operates in the health and care technology sector, delivering software solutions with a strong focus on subscription-based services. The company derives most of its revenue from recurring subscriptions, complemented by transaction-based income and consulting services, and tracks key SaaS metrics such as ARR, net retention and churn to gauge its performance.
Average Trading Volume: 112,659
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.64B
See more insights into CARA stock on TipRanks’ Stock Analysis page.